Screening for Babesia microti in the U.S. blood supply

New England Journal of Medicine

Volumn 375, Issue 23, 2016, Pages 2236-2245

  Moritz, Erin D ^a   Winton, Colleen S ^a   Tonnetti, Laura ^a   Townsend, Rebecca L ^a   Berardi, Victor P ^b   Hewins, Mary Ellen ^b   Weeks, Karen E ^b   Dodd, Roger Y ^a   Stramer, Susan L ^a  

^a AMERICAN RED CROSS   (United States)

^b Cancer Research Unit VA Medical Center Research Division   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BABESIA MICROTI ANTIBODY; BABESIA MICROTI DNA; DNA; UNCLASSIFIED DRUG; PROTOZOAL DNA; PROTOZOON ANTIBODY;

ADULT; AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY TITER; ARRAYED FLUORESCENCE IMMUNOASSAY; ARTICLE; BABESIA MICROTI; BLOOD DONOR; BLOOD EXAMINATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; HAMSTER; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PARASITE LOAD; PIROPLASMOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RACE DIFFERENCE; REAL TIME POLYMERASE CHAIN REACTION; SEROCONVERSION; SEX DIFFERENCE; TRANSFUSION TRANSMITTED BABESIOSIS; UNITED STATES; ANIMAL; BABESIOSIS; BLOOD; CLINICAL TRIAL; FLUOROIMMUNOASSAY; FOLLOW UP; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; MASS SCREENING; PARASITOLOGY; TRANSMISSION;

ANIMALS; ANTIBODIES, PROTOZOAN; BABESIA MICROTI; BABESIOSIS; BLOOD; BLOOD DONORS; CRICETINAE; DNA, PROTOZOAN; FLUOROIMMUNOASSAY; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MASS SCREENING; REAL-TIME POLYMERASE CHAIN REACTION; UNITED STATES;

EID: 85003748575     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1600897     Document Type: Article

References (25)

1. Western KA, Benson GD, Gleason NN, Healy GR, Schultz MG. Babesiosis in a Massachusetts resident. N Engl J Med 1970; 283: 854-6.
2. Vannier EG, Diuk-Wasser MA, Ben Mamoun C, Krause PJ. Babesiosis. Infect Dis Clin North Am 2015; 29: 357-70.
3. Homer MJ, Aguilar-Delfin I, Telford SR III, Krause PJ, Persing DH. Babesiosis. Clin Microbiol Rev 2000; 13: 451-69.
4. Adams D, Fullerton K, Jajosky R, et al. Summary of notifiable infectious diseases and conditions - United States, 2013. MMWR Morb Mortal Wkly Rep 2015; 62(53): 1-122.
5. Leiby DA. Transfusion-transmitted Babesia spp.: bull's-eye on Babesia microti. Clin Microbiol Rev 2011; 24: 14-28.
6. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M. Transfusion- associated babesiosis in the United States: a description of cases. Ann Intern Med 2011; 155: 509-19.
7. Kessler DA, Erwin JL, Busch MP, Levin AE, Shaz BH. Serological findings in donors who are deferred for a history of babesiosis. Transfusion 2012; 52: Suppl: 211A. abstract.
8. Moritz ED, Winton CS, Johnson ST, et al. Investigational screening for Babesia microti in a large repository of blood donor samples from nonendemic and endemic areas of the United States. Transfusion 2014; 54: 2226-36.
9. Johnson ST, Cable RG, Tonnetti L, Spencer B, Rios J, Leiby DA. Seroprevalence of Babesia microti in blood donors from Babesia-endemic areas of the northeastern United States: 2000 through 2007. Transfusion 2009; 49: 2574-82.
10. Cullen JM, Levine JF. Pathology of experimental Babesia microti infection in the Syrian hamster. Lab Anim Sci 1987; 37: 640-3.
11. Brandt F, Healy GR, Welch M. Human babesiosis: the isolation of Babesia microti in golden hamsters. J Parasitol 1977; 63: 934-7.
12. Gleason NN, Healy GR, Western KA, Benson GD, Schultz MG. The "Gray" strain of Babesia microti from a human case established in laboratory animals. J Parasitol 1970; 56: 1256-7.
13. Tonnetti L, Proctor MC, Reddy HL, Goodrich RP, Leiby DA. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion 2010; 50: 1019-27.
14. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2014. Silver Spring, MD: Food and Drug Administration (http://www .fda .gov/downloads/BiologicsBlood Vaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM459461 .pdf).
15. Young C, Chawla A, Berardi V, Padbury J, Skowron G, Krause PJ. Preventing transfusion-transmitted babesiosis: preliminary experience of the first laboratorybased blood donor screening program. Transfusion 2012; 52: 1523-9.
16. Eder AF, Meena-Leist CE, Hapip CA, Dy BA, Benjamin RJ, Wagner SJ. Clostridium perfringens in apheresis platelets: an unusual contaminant underscores the importance of clinical vigilance for septic transfusion reactions (CME). Transfusion 2014; 54: 857-62.
17. Eder AF, Dy BA, O'Neill EM. Predicted effect of selectively testing female donors for HLA antibodies to mitigate transfusionrelated acute lung injury risk from apheresis platelets. Transfusion 2016; 56: 1608-15.
18. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50: 1495-504.
19. Stramer SL, Notari EP, Krysztof DE, Dodd RY. Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety? Transfusion 2013; 53: 2449-58.
20. Bish EK, Moritz ED, El-Amine H, Bish DR, Stramer SL. Cost-effectiveness of Babesia microti antibody and nucleic acid blood donation screening using results from prospective investigational studies. Transfusion 2015; 55: 2256-71.
21. Acosta ME, Ender PT, Smith EM, Jahre JA. Babesia microti infection, eastern Pennsylvania, USA. Emerg Infect Dis 2013; 19: 1105-7.
22. Fang DC, McCullough J. Transfusiontransmitted Babesia microti. Transfus Med Rev 2016; 30: 132-8.
23. Ness PM, Lipton KS. Selective transfusion protocols: errors and accidents waiting to happen. Transfusion 2001; 41: 713-5.
24. Simon MS, Leff JA, Pandya A, et al. Cost-effectiveness of blood donor screening for Babesia microti in endemic regions of the United States. Transfusion 2014; 54: 889-99.
25. Transcript of the meeting of the Blood Products Advisory Committee, May 13, 2015. Silver Spring, MD: Food and Drug Administration (http://www .fda .gov/down loads/AdvisoryCommittees/Committees MeetingMaterials/BloodVaccinesandOther Biologics/BloodProductsAdvisory Committee/UCM449523 .pdf).